Everything you need to know about ketamine.
What is ketamine?
Ketamine is an anesthetic. It is a preferred choice in operating rooms and clinical settings today due to its excellent safety profile. First approved by the US Food & Drug Administration in 1970, Ketamine was originally brought to market as a safer alternative to existing anesthetics.
Ketamine as an antidepressant.
At the start of the 21st century, ketamine was found to be remarkably effective as an antidepressant when administered in low doses.
Ketamine triggers neuroplasticity (a state when your brain can more easily learn, change and adapt), allowing the brain to make new connections and disconnect from old patterns of thinking, which contribute to mental health symptoms. This creates a temporary window for establishing new habits, thought patterns, and perceptions.
Unlike traditional antidepressants which can take weeks to make an impact, Ketamine can rapidly reduce depressive symptoms within two hours of administration, and this relief can be sustained for up to two weeksfollowing just a single dose.
Why ketamine?
Safe
Ketamine has been studied as an anaesthetic for over 50 years.
Effective
As an antidepressant, ketamine has been proven to provide rapid and sustained relief.
Legal
Ketamine is approved for therapeutic use in the US and Canada.
Quick
Ketamine takes effect in minutes, and only lasts for about 45-90 minutes.
Flexible
Dosage is personalized throughout treatment, customized just for you.
Frequently asked questions.
Is ketamine a psychedelic?
Although ketamine works on different parts of the brain than classic psychedelics like psilocybin, the experiences on ketamine can be very similar.
Is ketamine safe?
How is ketamine taken at Field Trip?
How does ketamine feel?
Are there ketamine side effects?
The way ketamine is used can change its effectiveness.
While ketamine alone can be used as an antidepressant, there is mounting evidence suggesting that ketamine, when administered with psychotherapy, has longer lasting improvements in depression and anxiety severity. 4-6
- Zarate et al (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
- Yale Medicine, 2019
- Nutt, D. J., King, L.A., & Phillips, L. D. (2010), Drug harms in the UK: a multicriteria decision analysis. The Lancet, 376(9752). 1558-1565. https://doi.org/10.1016/s0140-6736(10)61462-6
- Dore J. et al (2019). Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy.
- aan het Rot, M. et al (2010). Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression
- Field Trip Health Preliminary Data, 2020-2022
EN 
FR 